Colorectal Cancer Detection Using Targeted LC-MS Metabolic Profiling

  • Danijel Djukovic
  • Jiangjiang Zhang
  • Daniel Raftery
Part of the Methods in Molecular Biology book series (MIMB, volume 1765)


Colorectal cancer (CRC) is one of the most commonly diagnosed malignancies and causes of cancer death. While the mortality rates from CRC have steadily declined, 50,000 individuals in the USA (and many times this number worldwide) still succumb to this illness every year. Early detection of CRC is the most critical need for improving 5-year survival and cure rates. Currently available CRC diagnostic techniques often miss early stage disease such that only 40% of newly diagnosed CRC patients are treated for local disease, Therefore, development of new screening methods that are highly sensitive, specific, noninvasive and easily accessible are critically desired for the early diagnosis and significant reduction in death rate from CRC. In this chapter we describe a targeted LC-MS based metabolic profiling approach used for the discovery of CRC metabolite biomarker candidates, based on highly reproducible hydrophilic interaction liquid chromatography coupled to triple-quadrupole mass spectrometry (HILIC-LC-QQQ-MS). A partial least squares-discriminant analysis (PLS-DA) model was able to differentiate CRC patients from both healthy controls and polyp patients, as well as to distinguish CRC patients based on the cancer stage.

Key words

Colorectal cancer (CRC) Polyps Metabolomics Targeted metabolic profiling LC-MS Metabolite biomarkers 


  1. 1.
    Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A (2017) Colorectal cancer statistics, 2017. CA Cancer J Clin 67:177–193CrossRefPubMedGoogle Scholar
  2. 2.
    Howlader N, Noone AM, Krapcho M (2016) SEER cancer statistics review, 1975-2013. National Cancer Institute, Bethesda, MDGoogle Scholar
  3. 3.
    Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM (2009) American College of Gastroenterology guidelines for colorectal cancer screening 2008. Am J Gastroenterol 104:739–750CrossRefPubMedGoogle Scholar
  4. 4.
    Bond JH (2003) Colon polyps and cancer. Endoscopy 35:27–35CrossRefPubMedGoogle Scholar
  5. 5.
    Ahlquist DA, Zou H, Domanico M, Mahoney DW, Yab TC, Taylor WR, Butz ML, Thibodeau SN, Rabeneck L, Paszat LF, Kinzler KW, Vogelstein B, Bjerregaard NC, Laurberg S, Sørensen HT, Berger BM, Lidgard GP (2012) Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 142:248–256CrossRefPubMedGoogle Scholar
  6. 6.
    Link A, Balaguer F, Shen Y, Nagasaka T, Lozano JJ, Boland CR, Goel A (2010) Fecal microRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomark Prev 19:1766–1774CrossRefGoogle Scholar
  7. 7.
    Ritchie SA, Tonita J, Alvi R, Lehotey D, Elshoni H, Myat S, McHattie J, Goodenowe DB (2013) Low-serum GTA-446 anti-inflammatory fatty acid levels as a new risk factor for colon cancer. Int J Cancer 132:355–362CrossRefPubMedGoogle Scholar
  8. 8.
    Gu H, Nagana Gowda GA, Raftery D (2012) Metabolic profiling: are we en route to better diagnostic tests for cancer? Future Oncol 8:1207–1210CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Nagana Gowda GA, Zhang S, Gu H, Asiago V, Shanaiah N, Raftery D (2008) Metabolomics-based methods for early disease diagnostics: a review. Expert Rev Mol Diagnost 8:617–633CrossRefGoogle Scholar
  10. 10.
    Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg Effect: the metabolic requirements of cell proliferation. Science 324:1029–1033CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu y NY, Zhao A, Xu LX, Cai S, Jia W (2009) Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res 8:4844–4850CrossRefPubMedGoogle Scholar
  12. 12.
    Tan B, Qiu Y, Zou X, Chen T, Xie G, Cheng Y, Dong T, Zhao L, Feng B, Hu X, Xu LX, Zhao A, Zhang M, Cai G, Cai S, Zhou Z, Xheng M, Zhang Y, Jia W (2013) Metabonomics identifies serum metabolite markers of colorectal cancer. J Proteome Res 12:3000–3009CrossRefPubMedGoogle Scholar
  13. 13.
    Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W (2012) Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res 11:1354–1363CrossRefPubMedGoogle Scholar
  14. 14.
    Nishiumi S, Kobayashi T, Ikeda A, Yoshie T, Kibi M, Izumi Y, Okuno T, Hayashi N, Kawano S, Takenawa T, Azuma T (2012) A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS One 7:e40459. Scholar
  15. 15.
    Farshidfar F, Weljie AM, Kopciuk K, Buie WD, Anthony ML, Dixon E, Sutherland FR, Molckovsky A, Vogel HJ, Bathe OF (2012) Serum metabolic profile as a means to distinguish stage of colorectal cancer. Genome Med 4:42–54CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Ritchie SA, Ahiahonu PWK, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB (2010) Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med 8:13–32CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Li F, Qin X, Chen H, Qiu L, Guo Y, Liu H, Chen G, Song G, Wang X, Li F, Guo S, Wang B, Li Z (2013) Lipid profiling for early diagnosis and progression of colorectal cancer using direct-infusion electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. Rapid Commun Mass Spectrom 27:24–34CrossRefPubMedGoogle Scholar
  18. 18.
    Zhu J, Djukovic D, Deng L, Gu H, Himmati F, Chiorean EG, Raftery D (2014) Colorectal cancer detection using targeted serum metabolic profiling. J Proteome Res 13:4120–4130CrossRefPubMedGoogle Scholar
  19. 19.
    Zhu J, Djukovic D, Deng L, Gu H, Himmati F, Chiorean EG, Zaid MA, Raftery D (2015) Targeted serum metabolite profiling for colorectal cancer progression monitoring. Anal Bioanal Chem 407:7857–7863CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Danijel Djukovic
    • 1
  • Jiangjiang Zhang
    • 1
  • Daniel Raftery
    • 1
  1. 1.Department of Anesthesiology and Pain MedicineUniversity of WashingtonSeattleUSA

Personalised recommendations